Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — H1 2022 Earnings Presentation
19 slides from Novo Nordisk A/s Class B's earnings presentation, Aug 4, 2022
Slide 1: Novo Nordisk – a focused healthcare company
Novo Nordisk –a focused healthcare company Investor presentation First six months of 2022 Morten Kruse Jacobsen (to the right), Senior Director at Novo Nordisk and married to Anders. Being a sustainable employer is a key priority for Novo Nordisk. This includes fostering a diverse and inclusive work
Slide 2: Agenda
2 Investor presentation First six months of 2022 Novo Nordisk® Progress on Strategic Aspirations 2025 Agenda Agenda Commercial execution Innovation and therapeutic focus Financials
Slide 3: Forward-looking statements
3 Investor presentation First six months of 2022 Novo Nordisk® Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the statutory Annual Report 2021 and Form 20-F, which both were filed with the SEC in February 2022 i
Slide 4: Strategic Aspirations 2025 – Highlights first six months of 2022
4 Investor presentation First six months of 2022 Novo Nordisk® Strategic Aspirations 2025 | Highlights first six months of 2022 Light blue indicates developments in Q2 2022 Further raise innovation bar for Diabetes treatment: Progress towards zero environmental impact: • Successful completion of fiv
Slide 5: Sales growth of 16% driven by both operating units
5 Investor presentation First six months of 2022 Novo Nordisk® Sales growth of 16% driven by both operating units Reported geographic sales split for first half of 2022 Reported therapy area sales and growth for first half of 2022 DKK Insulin GLP-1 Other diabetes DKK North America Operations Interna
Slide 6: Diabetes value market leadership increased by 1.5%-points to 31%
6 Investor presentation First six months of 2022 Novo Nordisk® Diabetes value market leadership increased by 1.5%-points to 31% Novo Nordisk global diabetes value market share Diabetes value market leadership expansion driven by the GLP-1 franchise 60% Diabetes GLP-1 Insulin Diabetes care sales grew
Slide 7: GLP-1 performance drives Diabetes care sales growth in International Operations
7 Investor presentation First six months of 2022 Novo Nordisk® GLP-1 performance drives Diabetes care sales growth in International Operations and Ozempic® is now the leading brand Reported Diabetes care sales and growth per IO geography GLP-1 patients and value market share in IO DKK Number of Valu
Slide 8: GLP-1 class expansion continues in the US as new prescriptions have accelerated
8 Investor presentation First six months of 2022 Novo Nordisk® GLP-1 class expansion continues in the US as new prescriptions have accelerated in the second quarter of 2022 US GLP-1 weekly NBRx prescriptions US GLP-1 TRx market share Weekly NBRx TRx share Total GLP-1 scripts (‘000) Class growth >35%
Slide 9: Obesity care sales grew by 84% in the first half of 2022
9 Investor presentation First six months of 2022 Novo Nordisk® Obesity care sales grew by 84% in the first half of 2022 driven by both the US and IO NN sales and market share Global Branded AOM TRx within Obesity care DKK TRx count (‘000s) billion 3%1 55%1 84%1 400 +63% 3.7 84% 90% The US 3.1 300 •
Slide 10: Rare disease sales were unchanged at constant exchange rates
10 Investor presentation First six months of 2022 Novo Nordisk® Rare disease sales were unchanged at constant exchange rates Reported Rare disease sales Rare disease sales driven by global commercial execution DKK billion Growth at CER 12 0% 3% 1% 6% 3% -5% Rare disease sales remain unchanged, drive
Slide 11: Once-weekly insulin icodec demonstrated superior HbA1c reduction in ONWARDS 1-3 trials
11 Investor presentation First six months of 2022 Novo Nordisk® Once-weekly insulin Icodec demonstrated superior HbA1c reduction in people with type 2 diabetes in ONWARDS 1-3 trials ONWARDS 1 2 3 4 5 6 Basal initiation Basal switch Basal initiation Basal/Bolus Basal initiation Basal/Bolus Duration 5
Slide 12: ONWARDS achieved primary endpoint of HbA1c non-inferiority
12 Investor presentation First six months of 2022 Novo Nordisk® ONWARDS 4 achieved primary endpoint of HbA1c non-inferiority with no statistically significant difference in hypoglycaemic events Change in HbA1c from baseline over time 26 weeks Overall hypoglycaemic episodes in the trial Time since ra
Slide 13: SELECT cardiovascular outcomes trial continues following interim analysis
13 Investor presentation First six months of 2022 Novo Nordisk® Following an interim analysis, the SELECT cardiovascular outcomes trial continues in accordance with the trial protocol Objective SELECT trial with 17,500 people with obesity Demonstrate that semaglutide 2.4 mg lowers the incidence of M
Slide 14: R&D milestones for 2022
14 Investor presentation First six months of 2022 Novo Nordisk® R&D milestones for 2022 Clinical milestones1 Regulatory milestones1 Project Q2 2022 Q3 2022 Q4 2022 Diabetes care FDC Sema – OW GIP Phase 1 results CagriSema T2DM Phase 2 results Rybelsus® CN submission Icodec Phase 3a results Higher do
Slide 15: Financial results – First six months of 2022
15 Investor presentation First six months of 2022 Novo Nordisk® Financial results – First six months of 2022 First six First six Change Change In DKK million months of 2022 months of 2021 (reported) (CER) Sales 83,296 66,845 25% 16% Gross profit 70,310 55,487 27% 17% Gross margin 84.4% 83.0% Sales a
Slide 16: Attractive capital allocation to shareholders
16 Investor presentation First six months of 2022 Novo Nordisk® Attractive capital allocation to shareholders Annual cash return to shareholders Capital allocation DKK billion 50 • Return of free cash flow through both share buy-backs and dividends 40 • For 2021, the total dividend per share increas
Slide 17: Financial outlook for 2022
17 Investor presentation First six months of 2022 Novo Nordisk® Financial outlook for 2022 Expectations Expectations 3 August 2022 29 April 2022 Sales growth – at CER 12% to 16% 10% to 14% Sales growth - reported Around 9 percentage points higher Around 7 percentage points higher Operating profit gr
Slide 18: Strategic aspirations 2025
18 Investor presentation First six months of 2022 Novo Nordisk® Strategic aspirations 2025 • Further raise the innovation-bar for diabetes treatment therapeutic focus • Progress towards zero environmental impact • Develop a leading portfolio of superior treatment Innovation and solutions for obesity
Slide 19: Investor contact information
19 Investor presentation First six months of 2022 Novo Nordisk® Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the Investor Relations